Endocrine Abstracts

Background: Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE (LUTATHERA) is an effective treatment option for somatostatin receptor (SSTR) positive metastatic gastroenteropancreatic neuroendocrine tumors (NETs) and has also demonstrated antitumor activity in SSTR positive NETs from other primary sites. While the median progression free survival (mPFS) is around 29 months, there is a subset of patients who are refractory to PRRT and demonstrate progressio...

Introduction: Our previous study has shown low rates of inpatient deintensification and high rates of adverse outcomes in people with diabetes and frailty1. The diabetes in reach (DiR) team consists of diabetologists working together with diabetes specialist nurses, proactively supporting non-specialists in the inpatient management of diabetes. This could be done either virtually or by face-to-face review in the medical ward. This study assessed the role of the DiR ...

Background: Immune checkpoint inhibitor (ICI) maintenance therapy is the standard of care for frontline management of extensive-stage small cell lung cancer (ES SCLC). However, the overall survival benefit of the addition of ICI maintenance to frontline ES SCLC treatment is modest and further improvement is needed. We hypothesized that the addition of poly (ADP-ribose) polymerase inhibition to ICI maintenance therapy for patients with platinum-sensitive ES SCLC could improve t...